-
Firefighters push to 'encircle' Belgian wildfire
-
Crude extends gains, most stocks drop as Mideast hopes dim
-
ISS to host first spacewalk by Frenchwoman
-
Rift deepens as Asia football chief hits back at Qatar in Infantino saga
-
Philippine student killed in livestreamed school shooting
-
India extend lead to 294 in first Sri Lanka Test
-
More Trump-Kim 'love'? What we know about North Korea
-
Asian allies stress 'critical cooperation' as Trump slashes Korea drills
-
Major Meta trial begins as lawyers spar over witnesses, damages
-
Williams sisters fall at Cincinnati while Zverev advances
-
Trump threatens to bomb Oman if it gets in way of Iran deal
-
Transylvania's fortified churches face fragile future
-
Australian cricketer Warner ordered to use breathalyser vehicle lock
-
China mourns former premier Zhu Rongji with flags lowered, funeral
-
A Viking longship in 'The Odyssey'? It's a case of history meets Hollywood
-
Philippine student killed in rare school shooting
-
Racist abuse spurred Suzuki as Japan goalkeeper set for Premier League
-
Arsenal primed for Premier League title defence as rivals face questions
-
Japan lights torch as countdown begins to Asian Games
-
Zverev advances at Cincinnati while Williams sisters fall
-
Make it rain: Indonesia chases clouds to stem El Nino fires
-
Copper powers profit rise at mining giant BHP
-
All aboard as Asian Games preparations enter 'final stages'
-
Whales spark joy in New York but face threats from boat traffic
-
Lights out, crowds gone: Havana waits for what comes next
-
Premier League's new bosses brace for battle
-
How families in Milei's Argentina sank deep into debt
-
Zambia's Hichilema: 'cattle boy' and two-time president
-
Zambia's Hichilema wins re-election with 60% of vote
-
Elderly far more at risk from rising heat than thought: study
-
Jeanie Buss to fight siblings over sale of 17.8% stake in Lakers: reports
-
Brazil's Lula hails new oil find as 'passport to the future'
-
Paramount demands $1.9 billion surety over states' merger lawsuit
-
Rybakina slogs through double rain delays in Cincinnati win
-
Latest developments in US-Iran war
-
Two largest US reservoirs hit record lows amid western drought
-
NBA has no evidence of Clippers salary cap cheating: report
-
Colombian minister under fire over beach holiday post-quake
-
Boehly and Walter consider selling Chelsea stake to Clearlake Capital
-
Lamour leaves key FIFA position after criticising Infantino
-
OpenAI to lease massive new AI data center in US, backed by Nvidia
-
Buss family sells 17.8% stake in Lakers to Iger group
-
US stocks fall on spiking bond yields, higher oil prices
-
Mangione state murder trial postponed after federal guilty plea
-
LIV Golf cancels Michigan event, to decide team title at Indy
-
Trump envoy says Hamas disarmament could begin within 30 days
-
Rodri arrives at Barcelona to complete 'dream' move
-
US pauses construction of border project in Texas national park
-
Discord suspends livestreams in Brazil after teen's suicide
-
Thousands mourn dead black academic in London vigil
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
A.AbuSaada--SF-PST